Cardiac transplantation is the definitive
|
|
- Sheryl Bennett
- 8 years ago
- Views:
Transcription
1 HEART TRANSPLANTATION: GRAFT REJECTION BASICS * Howard J. Eisen, MD ABSTRACT The alloimmune response is central to graft rejection. In the cellular response, recipient T cells recognize foreign antigen presented in a complex with major histocompatibility complex (MHC) proteins on the surface of specialized antigen-presenting cells. If the interaction between the T-cell receptor and the MHC complex is accompanied by appropriate costimulatory signals, then other signals and cytokines are triggered and the T cell proliferates and rejection ensues. Activated B cells produce antibodies that are graft specific. By targeting various steps in the recognition, proliferation, or activation phase of the alloimmune response, immunosuppressive agents alone or in combination can inhibit T-cell action and thereby reduce the risk of acute rejection. Because the alloimmune response also contributes to cardiac allograft vasculopathy, immunosuppressive agents may also limit this type of chronic rejection. Gene expression tests that measure the up- or downregulation of specific molecular and cell pathways are being developed as an alternative to the standard biopsy-based diagnosis of rejection. This review will discuss the alloimmune response, the mechanisms of immunosuppressive agents, and molecular diagnosis of graft rejection. (Adv Stud Med. 2008;8(6): ) *Based on a presentation by Dr Eisen at a roundtable held in Parsippany, New Jersey, on February 9, Thomas J. Vischer Professor of Medicine, Drexel University College of Medicine, Chief, Division of Cardiology, Hahnemann University Hospital, Philadelphia, Pennsylvania. Address correspondence to: Howard J. Eisen, MD, Division of Cardiology, Drexel University College of Medicine, 245 North 15th Street, Mailstop #1012, Philadelphia, PA howard.eisen@drexelmed.edu. Cardiac transplantation is the definitive therapy for patients with end-stage heart failure. Approximately 2000 such procedures are now performed every year in the United States. 1 Although survival has improved over the last several decades as a result of better immunosuppressive regimens and infection control, graft rejection remains a major limitation to survival. The alloimmune response is central to graft rejection, not only in the early posttransplant period as part of classic acute rejection, but also in the later posttransplant period when it likely contributes to chronic rejection or cardiac allograft vasculopathy (CAV). This article describes the fundamental pathways of the alloimmune response, reviews the mechanisms of various immunosuppressive agents, and provides an update on molecular methods of rejection diagnosis. UNDERSTANDING THE ALLOIMMUNE RESPONSE After transplantation, several components of the recipient s immune system are mobilized against the graft. The recipient s T cells, B cells, and natural killer cells recognize the allograft because of the plethora of nonself major histocompatibility complex (MHC) antigens on the graft cells. Two general types of MHC antigens, class I and class II, are expressed on the surface of the allograft endothelial and parenchymal cells. These MHC antigens are large molecules made up of separate peptide chains and often, but not always, an associated foreign peptide. Within the human population, there are hundreds of allelic variations for each of the major segments of the MHC molecule. This underlying genetic diversity explains the tremendous heterogeneity seen between individuals in terms of MHC antigens. It also explains the near impossibility of finding a close match in heart transplantation. 2 The recipient s B and T cells recognize alloantigens in different fashions that, in turn, produce different results. Activated B cells produce specific antibodies 174 Vol. 8, No. 6 May 2008
2 that bind to alloantigens (not just MHC antigens) in a way that focuses components of the innate immune system. In the classic complement pathway, complement binding to the antibodies and subsequent activation results in vascular injury and damage to the allograft. Activated macrophages and other immune cells may also bind to the antibodies, leading to antibody-mediated cell lysis. As discussed later, detection of complement or macrophages in the graft provides evidence of antibody-mediated rejection. Recall that the antibodies and the receptors found on the B and T cells, respectively, have highly variable regions that only become specific for antigen when the naïve cell is activated or mature. 3 The T cells recognize alloantigens in 1 of 2 ways. In the direct pathway, the T-helper cell recognizes a foreign antigen on the graft cell itself; this foreign antigen is often associated with an MHC complex on the donor s antigen-presenting cells (ie, an allogeneic antigen-presenting cell [APC]). In the indirect pathway, the foreign antigen is first broken down into small peptides by the recipient s own APCs (ie, a self APC), such as dendritic cells, and these peptides are presented to naïve T cells in a complex with the recipient MHC antigens. 2 In response, activated T-helper cells (CD4+) proliferate and produce cytokines that stimulate production of cytotoxic T cells (CD8+), B cells, and macrophages. All of these elements, spurred by the CD4+ T cell, cause destruction of the graft by direct lysis of target cells, antibody production, and delayedtype hypersensitivity reactions (Figure 1). 4 The interactions between the MHC-peptide complex on the APCs and the receptors on the T cells are central to the complete alloimmune response. 5 The interaction is often initiated by interdigitating dendritic cells, which are capable of recognizing potentially harmful foreign microorganisms or nonself constituents and can also be stimulated by endogenous activators, such as interferon α, heat-shock proteins, and tumor necrosis factor, released during infection. Dendritic cells break down the foreign antigen into smaller peptides and present these peptides in conjunction with MHC class II molecules at their cell surface. This presentation occurs in the secondary lymphoid tissues where T cells ordinarily circulate. When the MHC complex is bound by receptors on the naïve T cell, both cells begin to express a variety of costimulatory molecules. These cell surface molecules provide the type of second, third, and fourth handshakes that are needed to ramp up the full immune response. This costimulation is provided, for example, by interactions of T cell CD28 with APC CD80/CD86 (also called B7) and also by T cell leukocyte function-associated antigen 1 with intercellular adhesion molecule 1. Such costimulatory signals are required for lymphocyte activation; without them, anergy or apoptosis will occur. 3,6 Blocking interactions between the paired receptors involved in costimulation is a goal for many next-generation antirejection drugs. Once a T cell is appropriately stimulated at the surface, a variety of events are prompted in the cytoplasm and nucleus. This downstream signaling involves several biochemical pathways and transcriptional activities that ultimately result in cell proliferation and differentiation. For example, 3 signal transduction pathways (calcium-calcineurin, mitogen-activated protein kinase, and protein kinase C-nuclear factor κ B) activate transcription factors that lead to the production of interleukin-2 (IL-2) receptor and IL-2 itself. This cytokine stimulates T-cell proliferation and, thus, via costimulation the T cell is able to fuel its own activation via generation of IL- 2. Both IL-2 and IL-15 deliver growth signals through the phosphoinositide-3-kinase pathway and the molec- Figure 1. Pathways of Recognition of Allogeneic MHC Molecules in Graft Rejection Direct Pathway Indirect Pathway Allogeneic APC Allogeneic APC Self-APC CD8 T C T C Activated cytotoxic T cell MHC molecule T-cell CD4 receptor B cell T H Alloantibodies Allogeneic peptide CD4 Cytokines Macrophage Delayed-type hypersensitivity APC = antigen-presenting cell; CD = complementarity determining region; MHC = major histocompatibility complex; T C = T cell; T H = T-helper cell. Reprinted with permission from Sayegh and Turka. N Engl J Med. 1998;339: T H Johns Hopkins Advanced Studies in Medicine 175
3 Figure 2. Mechanisms of Acute and Chronic Rejection Acute Rejection Within days of transplantation CMI response to donor MHC (CTLs attack donor tissue) Ab response also contributes Parenchymal cells Chronic Rejection Months to years after transplantation Slow, progressive loss of function Proliferation of fibroblasts and vascular cells Probably due to cytokines secreted by alloreactive T cells Vascular smooth muscle cell Alloreactive CD8+ T cell Alloreactive antibody Endothelial cell Cytokines APC Alloantigenspecific CD4+ T cell Macrophage Parenchymal cell damage, interstitial inflammation Endothelialitis Chronic DTH reaction in vessel wall, intimal smooth muscle cell proliferation, vessel occlusion Ab = antibody; APC = antigen-presenting cell; CD = complementarity determining region; CMI = cell-mediated immunity; CTL = cytotoxic T lymphocyte; DTH = delayed-type hypersensitivity. Reprinted with permission from Abbas and Lichtman. Basic Immunology: Function and Disorders of the Immune System. 2nd ed. Philadelphia, PA: Saunders Company; ular target of rapamycin (mtor) pathway, which initiates the cell cycle. 7 In attempting to clarify this complex and multistep process, only a portion of which is covered here, some researchers have described 3 key signals required for cellular rejection. In this 3-step model, Signal 1 is the T-cell receptor binding to the MHC complex on the APC, Signal 2 consists of the costimulatory binding, and Signal 3 involves the binding of IL-2 to the IL-2 receptor. 7 The end result of this 3-step T-cell activation is all too clear to the transplant cardiologist. Without appropriate medical therapy, acute rejection can occur within days of transplantation (Figure 2). 8 Antigenexperienced T cells infiltrate the graft and create endothelial inflammation (eg, tubulitis and endothelial arteritis), in addition to rejection lesions in the parenchyma or cardiac myocyte. This is mainly a cellmediated immune response but antibodies may contribute as well. If acute rejection does not destroy the graft, adaptation occurs and can be stabilized by immunosuppressive drugs. Although it also enlists elements of the alloimmune response, chronic rejection (Figure 2) also involves nonimmunologic mechanisms and is a fundamentally different pathophysiologic process. 8 Ischemia-induced injury to the donor endothelium initiates a broad cascade of immunologic and inflammatory responses, including upregulation of complement, inflammatory mediators, chemoattractants, and cytokines. The end result, seen over a period of weeks and months, is vascular smooth muscle proliferation and the development of neointimal hyperplasia, matrix deposition, and lumen narrowing that is commonly known as chronic rejection of CAV. 9,10 MECHANISMS OF IMMUNOSUPPRESSIVE DRUGS The primary goal of immunosuppression is to blunt the alloimmune response just described and thereby to prevent rejection. The targets of the main immunosuppressive agents are illustrated in Figure 3 11,12 and can be summarized as follows: Calcineurin inhibitors (eg, cyclosporine and tacrolimus): Inhibit T-cell proliferation and activation via inhibition of calcineurin and, subsequently, IL-2 expression. Antiproliferative agents (eg, azathioprine and mycophenolic acid): Inhibit T-cell proliferation via inhibition of purine synthesis (necessary for DNA replication). Corticosteroids: Exert potent immunosuppressive and anti-inflammatory effects by altering transcription factors that control genes affecting growth factors, cytokines, and adhesion factors. Among the many synergistic and complementary effects of steroids, these agents inhibit production of IL-6 and, to some degree, IL-2. Proliferation signal inhibitors (eg, sirolimus and everolimus): Inhibit the mtor after autocrine stimulation by IL-2 (thereby complementary to calcineurin inhibitors) to slow proliferation of T cells; these agents also inhibit proliferation of the 176 Vol. 8, No. 6 May 2008
4 Figure 3. Mechanism of Action of Immunosuppressive Drugs Steroids T cell B7 Steroids Nucleus APC CD28 Ciclosporin Tacrolimus CD3 Calcineurin NFAT Cytokine mrna eg, IL-2 MHC-II + peptide TCR IL-2 CD4 TOR Cyclin/CDK IL-2R Ab IL-2R Ab = antibody; APC = antigen-presenting cell; CD = complementarity determining region; IL-2 = interleukin-2; IL-2R = interleukin-2 receptor; MHC = major histocompatibility complex; MMF = mycophenolate mofetil; mrna = messenger ribonucleic acid; NFAT = nuclear factor of activated T cells; TCR = T-cell receptor; TOR = target of rapamycin. Reprinted with permission from Kobashigawa and Patel. Nat Clin Pract Cardiovasc Med. 2006;3: vascular smooth muscle cells typically seen in response to endothelial injury. Although sirolimus binds to the same protein as tacrolimus (FK binding protein-12), it does not inhibit calcineurin and the related IL-2 production; rather, it binds to mtor, which blocks translation initiation and, ultimately, a variety of CD28 and IL- 2 driven proliferation signals. 13 Induction therapy (eg, anti IL-2 receptor antibodies, anti-cd3 antibodies, and antithymocyte globulins): Intense perioperative immunosuppression usually involves use of agents such as: (1) basiliximab or daclizumab, which prevent IL-2 binding to the IL-2 receptor and thereby inhibit T-cell proliferation and activation; (2) anti-cd3 antibodies, such as murine monoclonal CD3 antibody, which blocks the T-cell receptor from binding to the antigen-presenting MHC antigens; and/or (3) antithymocyte globulin, which has an unknown mechanism but which inhibits a variety of T-cell receptors and proteins. 7 G1 M Sirolimus Everolimus S Cell cycle G2 MMF Azathioprine Thus, the transplant specialist has a range of immunosuppressive tools that target, at varying levels and to different degrees, 2 of the 3 main signals involved in T-cell proliferation and activation. In terms of Signal 1, the anti-cd3 antibodies block MHC/peptide surface interactions with the T-cell receptor; the calcineurin inhibitors block the downstream actions of the stimulated CD3 receptor. Regarding Signal 3, the IL-2 receptor antibodies block the critical CD25 receptor on the cell surface while the mtor inhibitors and antiproliferative agents interrupt specific steps in the chain of events following IL- 2 stimulation. Several agents, including an anti-cd154 monoclonal antibody and CTLA-4-Ig (an immunoglobulin fragment that blocks CD80/CD86, or B7), are in development to target Signal 2. 4 The goal is that one or more of these investigational agents will eventually be shown to block the critical costimulation step and thereby elicit a prolonged state of T-cell quiescence even after foreign antigens are recognized in Signal 1. Photopheresis is another method that is occasionally used in patients having severe rejections not responding to standard immunosuppressive therapies. This method involves removing white blood cells, treating them with methoxypsoralen, irradiating them with ultraviolet light, washing out the methoxypsoralen, and then returning the cells to the patient. Although the exact mechanism is unclear, this method appears to target proliferating cells and a randomized trial (N = 60) has documented a reduced mean number of rejections (0.91 vs 1.44, P =.04) at 6 months after transplant. 14 UPDATE IN DIAGNOSING CELLULAR REJECTION The most well-defined method for diagnosing cellular rejection still involves endomyocardial biopsy. This invasive surveillance involves 13 to 15 biopsies in the first year. Generally the sampling device is guided by echocardiogram or X ray through the internal jugular vein to the apex of the right ventricle. For a meaningful survey, each biopsy requires a minimum of 3 cardiac samples from 3 different sites. In recent years, as discussed in the following sections, a new system has been introduced to grade cardiac biopsies and molecular methods have been developed to reduce the need for invasive sampling and also, possibly, to improve early prediction of rejection events. Johns Hopkins Advanced Studies in Medicine 177
5 The endomyocardial biopsy is also used to diagnose antibody-mediated vascular rejection. Typically detected in the capillaries, this procedure often involves immunofluorescent staining of specimens for complement fragments C4d, C3c, and/or C1q. Another method is immunohistochemical staining for the CD68 antigen, which is associated with macrophages. Paraffin immunohistochemistry for C4d and standard hematoxylin and eosin staining of the capillaries are probably still the most common approaches. Deploying a combination of these techniques on the biopsy specimen will reveal antibody-related rejection activity, endothelial edema, and cellular infiltration; performed serially, the techniques will also show diminished staining as a rejection episode abates with treatment. 15 NEW PATHOLOGIC CRITERIA The old scoring system promulgated by the International Society for Heart and Lung Transplantation (ISHLT) classified the severity of rejection into 4 grades based on the extent of the lymphocyte or inflammatory infiltrate in the myocytes and also the extent of myocyte parenchymal damage. 16 In this 1990 grading system, rejections graded as 0 or 1A or 1B would not be treated. The new system is based on the same criteria of infiltration and myocyte damage but combines several of the older classifications to create a simpler mild-moderate-severe grading of rejection (Table). 16,17 In this new system, only grade 2R (moderate) and grade 3R (severe) require treatment; the old grade 2 specimen with focal infiltrate is now considered mild and not treated. NEW MOLECULAR METHODS In an attempt to produce less invasive methods for detecting rejection, a variety of gene expression tests on peripheral blood cells have been developed. Such tests, which measure the expression of select genes thought to be upregulated or downregulated during rejection, hold the potential for a more objective standard of classification and also potentially an earlier warning of impending rejection. The development of one such expression test in the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study illustrates the processes, assumptions, and clinical potential inherent in the new genomic-based assays. In CARGO, microarrays and then quantitative real-time polymerase chain reaction tests were used to identify genes that strongly correlated with the presence or absence of acute cellular rejection (Figure 4). 18 The genes were selected and then validated based on comparison of expression results with biopsy results found in blinded pathology scoring in the same patient. Eventually, the hundreds of genes initially evaluated in early development were winnowed to the more practical number of approximately 20 in the current version of the diagnostic test. These selected genes are thought to play a role in a variety of pathways involved in response to the allograft including T-cell or macrophage activation, T-cell migration, platelet activation, inflammation, steroid responsiveness, and hematopoiesis. 18 Results from the CARGO study to date indicate that the test successfully distinguishes grade 3A or greater (moderate-to-severe) rejection from grade 0 rejection (P <.0001) and also from grades 1A or 2 (mild) rejection (P <.05; 1990 grading system). 18,19 Significantly, if a patient maintains a low gene expres- Table. Grading of Acute Cellular Rejection in Cardiac Biopsies: Criteria for Classification with Comparison of Old and New Grading Systems Criteria/Description Old Grading 16 New Grading 17 No evidence of rejection 0 0 } Focal perivascular and/or interstitial 1A infiltrate without myocyte damage (Mild-Focal) Diffuse infiltrate without myocyte 1B 1R damage (Mild-Diffuse) (Mild) One focus of infiltrate with myocyte 2 damage (Moderate-Focal) Multifocal infiltrate with myocyte 3A 2R damage (Moderate-Multifocal) (Moderate) Diffuse infiltrate with myocyte damage 3B (Moderate-Diffuse) Diffuse polymorphous infiltrate with 4 3R extensive myocyte damage ± edema (Severe) (Severe) ± hemorrhage ± vasculitis Treatment Required Data from Billingham et al 16 and Stewart et al. 17 } } } 178 Vol. 8, No. 6 May 2008
6 Figure 4. Process for Identifying Relevant Genes for Practical Expression Testing in Cardiac Rejection (from the CARGO Study) gene sequences Subtracted and suppressed leukocyte cdna libraries Sequence database mining: UniGene, SAGE, RefSeq Published literature: MEDLINE T T C C A C A C A A C A T A C G A G C C G G A A sion score beyond the first year after transplantation, there appears to be an extremely low risk of biopsyproven rejection (negative predictive value for ISHLT grade 3A rejection >99%). Therefore, such a blood test might allow a clinician to identify patients who do not need endomyocardial biopsies. This and other tests are still in development, and the clinical significance of the data remains to be defined. CONCLUSIONS Many novel immunosuppressive agents are under active clinical investigation and several creative approaches to improve the safe and effective use of established immunosuppressive drugs are also being developed. As these new strategies and tools mature, clinicians must maintain awareness of the alloimmune response pathways that provide the prime targets of opportunity for much of our clinical treatment in the posttransplantation period. DISCUSSION 8000 genes Leukocyte microarray 200 genes Array expression Real-time profiling Acute rejection PCR correlated markers Dr Kobashigawa: We have entered a great era in transplantation. In the past, we have had to rely on the 14 gene panel assays Acute rejection, gene expression panel assays CARGO = Cardiac Allograft Rejection Gene Expression Observational; cdna = complementary deoxyribonuceic acid; PCR = polymerase chain reaction; SAGE = serial analysis of gene expression database. invasive heart biopsy to detect rejection. With AlloMap molecular expression testing (XDx, Brisbane, CA) we have a simple blood test that can actually tell us whether patients are at risk of rejection. We also now have the ImmunKnow test (Cylex Inc., Columbia, MD) that tells us how immunoresponsive patients are by measuring the amount of adenosine triphosphate (ATP) that T cells make. Activated T cells make a lot of ATP, which means that immunosuppressed patients have lower amounts of ATP. This is most often a good thing, but too much immunosuppression increases the risk of infection. Thus, low test results indicate overimmunosuppression, mid-level results indicate proper immunosuppression, and higher results suggest that there is not enough immunosuppression on board. Studies in kidney and liver transplantation, and early data in heart transplant, suggest we can use this test to measure immunoresponsiveness rather than simply measuring blood levels of our immunosuppressive agents. Dr Russell: In our hands, the ImmunKnow test seems to be better at identifying overimmunosuppressed patients at increased risk for infection more than underimmunosuppressed patients at increased risk for rejection. Have you detected both the highs and the lows? Dr Kobashigawa: In our first experience with 46 patients, we did pick up patients who developed rejection. They had a mean ImmunKnow score of approximately 400. Those with scores below 200 or so had more infection. In our experience, the heart transplant patients should probably be between 200 and 350. Dr Rogers: I like this movement toward a more personalized approach to manipulating immunosuppressive therapy. We have been lulled into thinking that immunosuppressive drug levels provide a comprehensive view of the immunosuppressed state. Dr Eisen: Yes, these types of tests may eventually help us stave off late problems associated with overimmunosuppression, such as malignancy. Dr Conte: Have these tests already impacted the scheduling or frequency of your endomyocardial biopsies? Dr Eisen: Yes, in our program the AlloMap test, which was evaluated in the CARGO study, has resulted in a decline in biopsies beyond 6 months. For patients below a certain AlloMap threshold and without evidence of allograft dysfunction, we have elimi- Johns Hopkins Advanced Studies in Medicine 179
7 nated biopsies. We still need more information on the test s usefulness in the first 6 months before we start eliminating early biopsies. Dr Kobashigawa: At this point, we have shown these 2 tests can detect risk for rejection, but we need studies to see if they can actually predict rejection and guide therapy to improve outcomes. The IMAGE (Invasive Monitoring Attenuation Through Gene Expression) trial with AlloMap is doing that now. Also, we should keep in mind that these tests are complementary, with the ImmunKnow test gauging the state of immunosuppression and the AlloMap test detecting low risk for rejection. Dr Rogers: How often do you test tissue for markers of antibody-mediated rejection? And what are you actually staining for? Dr Eisen: In our program, we do not routinely check for C4d or other complement markers unless we suspect antibody-mediated rejection due to, for example, graft dysfunction. And then only in the absence of significant cellular rejection would we initiate therapies for antibody-mediated rejection therapies such as plasmapheresis to remove the antibodies, an anti-b cell agent like rituximab, or more traditional agents like cyclophosphamide or intravenous immunoglobulin (IVIG) to inhibit B-cell function. Dr Kobashigawa: A National Institutes of Health Consensus Conference on humoral rejection in all organ transplantation established 4 criteria for the diagnosis of humoral rejection: (1) H&E (hematoxylin and eosin) for general staining and CD68 staining for intravascular macrophages in the capillaries; (2) immunohistochemistry staining to highlight antibodies on the endothelial cells; (3) circulating antibodies; and (4) cardiac or organ dysfunction. Of course, most of us do not employ all these specialty stains. Instead, we usually consider the diagnosis of antibody-mediated rejection when we see graft dysfunction but cannot find evidence of cellular rejection. In terms of the therapies, the most common are plasmapheresis and IVIG but we are seeing more use of rituximab and even antithymocyte globulin, which blocks not only T cells, but B cells and potentially plasma cells. Dr Rogers: Do you prospectively screen all your patients for antibody-mediated rejection? Dr Kobashigawa: We automatically look at the H&Es, and our pathologist also stains for CD68, CD3, CD20, and CD34. We also do C4d staining for complement but that is not absolutely necessary to make a diagnosis for antibody-mediated rejection. Dr Russell: If a patient is doing well and some of those stains come back positive, do you just monitor the patient or do you change therapy? Dr Kobashigawa: We actually studied patients with asymptomatic humoral rejection on the biopsy with normal ejection fraction by echo and found that these patients developed more CAV at 5 years compared to patients without humoral rejection. But we still do not have the data to tell us if we should treat these patients with agents like IVIG or high-dose corticosteroids empirically. We need more studies. Dr Eisen: We should note that a CARGO II trial in Europe is now evaluating whether or not gene expression testing can detect antibody-mediated rejection. REFERENCES 1. Department of Health and Human Services. US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients 2006 Annual Report; VI. Heart and Lung Transplantations Available at: Accessed February 16, Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000;343: Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. 2000;343: Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 1998;338: Klein J, Sato A. The HLA system. First of two parts. N Engl J Med. 2000;343: Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol. 2003;3: Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351: Abbas A, Lichtman A. Basic Immunology: Function and Disorders of the Immune System. 2nd ed. Philadelphia, PA: Saunders Company; Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med. 2000;1: Azuma H, Tilney NL. Immune and nonimmune mechanisms of chronic rejection of kidney allografts. J Heart Lung Transplant. 1995;14:S136-S Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now? Nat Clin Pract Cardiovasc Med. 2006;3: Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353: Vol. 8, No. 6 May 2008
8 13. Sehgal SN, Camardo JS, Scarola JA, et al. Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens. 1995;4: Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med. 1998;339: Tan CD, Baldwin WM 3rd, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med. 2007;131: Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant. 1990;9: Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24: Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6: Bernstein D, Williams GE, Eisen H, et al. Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients. J Heart Lung Transplant. 2007;26: Johns Hopkins Advanced Studies in Medicine 181
specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationImmunosuppressive drugs
Immunosuppressive drugs RJM ten Berge Afd. Inw. Geneeskunde AMC contents overview targets mechanism of action Effects on immune capacity measured by responses to vaccination Immune response 1 calcineurin
More informationName (print) Name (signature) Period. (Total 30 points)
AP Biology Worksheet Chapter 43 The Immune System Lambdin April 4, 2011 Due Date: Thurs. April 7, 2011 You may use the following: Text Notes Power point Internet One other person in class "On my honor,
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationT Cell Maturation,Activation and Differentiation
T Cell Maturation,Activation and Differentiation Positive Selection- In thymus, permits survival of only those T cells whose TCRs recognize self- MHC molecules (self-mhc restriction) Negative Selection-
More informationMicrobiology AN INTRODUCTION EIGHTH EDITION
TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein
More informationNatalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
More informationIKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics
Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationThe Immune System: A Tutorial
The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The
More informationB Cell Generation, Activation & Differentiation. B cell maturation
B Cell Generation, Activation & Differentiation Naïve B cells- have not encountered Ag. Have IgM and IgD on cell surface : have same binding VDJ regions but different constant region leaves bone marrow
More informationChapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
More informationSERVICE: Transplant - JHH, PGY 3 (or 4) SERVICE: Transplant - JHH, PGY 3 (or 4)
SERVICE: Transplant - JHH, PGY 3 (or 4) General description: The Sinai surgical residents will rotate in the Division of Transplantation at the Johns Hopkins Hospital at the end of their 3rd or during
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationActivation and effector functions of HMI
Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ
More informationGraft-versus-host disease (GvHD)
Graft-versus-host disease (GvHD) This information is an extract from the booklet Understanding donor stem cell (allogeneic) transplants. You may find the full booklet helpful. We can send you a free copy
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationThe Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense
The Immune System 2 Types of Defense Mechanisms Immune System the system that fights infection by producing cells to inactivate foreign substances to avoid infection and disease. Immunity the body s ability
More information2) Macrophages function to engulf and present antigen to other immune cells.
Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components
More informationANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1
AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL
More information2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationRecognition of T cell epitopes (Abbas Chapter 6)
Recognition of T cell epitopes (Abbas Chapter 6) Functions of different APCs (Abbas Chapter 6)!!! Directon Routes of antigen entry (Abbas Chapter 6) Flow of Information Barrier APCs LNs Sequence of Events
More informationSupplemental Material CBE Life Sciences Education. Su et al.
Supplemental Material CBE Life Sciences Education Su et al. APPENDIX Human Body's Immune System Test This test consists of 31 questions, with only 1 answer to be selected for each question. Please select
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: immune_cell_function_assay 11/2009 3/2016 3/2017 3/2016 Description of Procedure or Service Careful monitoring
More informationRheumatoid arthritis: an overview. Christine Pham MD
Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching
More informationThe role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015
The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response
More informationTransplant Options When You Don t Have a Good Match
Transplant Options When You Don t Have a Good Match 1 Transplant Options When You Don t Have a Good Match Being told you need a transplant may bring about many feelings, including anxiety and uncertainty.
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression
More information1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.
Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationLESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES
Introduction to immunology. LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES Today we will get to know: The antibodies How antibodies are produced, their classes and their maturation processes Antigen recognition
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationAsthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System
1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID
More informationThe Immune System. How your immune system works. Organs of the Immune System
UW MEDICINE PATIENT EDUCATION The Immune System How your immune system works The immune system is a network of special cells, tissues, and organs that defend the body against attacks from foreign invaders,
More informationPulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic
Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells
More informationImmunosuppression for Solid Organ and Bone Marrow Transplantation Thomas R Spitzer, MD
Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Prof. Thomas Spitzer Spitzer/HST-151 1 Immunosuppression for Solid Organ and Bone Marrow Transplantation
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationImmuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
More informationOKT3. ~ The first mouse monoclonal antibody. used in clinical practice in the field of transplantation ~
g944202 潘 怡 心 OKT3 ~ The first mouse monoclonal antibody used in clinical practice in the field of transplantation ~ As everybody knows, OKT3 is the first mouse monoclonal antibody produced for the treatment
More informationThe Immunopathogenesis of Relapsing MS
The Immunopathogenesis of Relapsing MS Olaf Stüve, M.D., Ph.D. Neurology Section VA North Texas Health Care System Dallas VA Medical Center Departments of Neurology and Neurotherapeutics University of
More informationVPM 152. INFLAMMATION: Chemical Mediators
General Pathology VPM 152 INFLAMMATION: Chemical Mediators CHEMICAL MEDIATORS OF INFLAMMATION Definition: any messenger that acts on blood vessels, inflammatory cells or other cells to contribute to an
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationWake Forest School of Medicine Department of General Surgery
Wake Forest School of Medicine Department of General Surgery TRANSPLANT SURGERY RESIDENT CURRICULUM (PGY-3) OVERVIEW This curriculum has largely been adapted from the curriculum for transplant surgery
More informationAntibody Function & Structure
Antibody Function & Structure Specifically bind to antigens in both the recognition phase (cellular receptors) and during the effector phase (synthesis and secretion) of humoral immunity Serology: the
More informationHapten - a small molecule that is antigenic but not (by itself) immunogenic.
Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:
More informationWelcome to Mini Med School at the Child & Family Research Institute
Glossary Welcome to Mini Med School at the Child & Family Research Institute On behalf of the Faculty and Staff at the Child & Family Research Institute (CFRI), we would like to welcome you to CFRI s
More informationVitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model
Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC
More informationHypersensitivity. TYPE I Hypersensitivity Classic allergy. Allergens. Characteristics of allergens. Allergens. Mediated by IgE attached to Mast cells.
Gel and Coombs classification of hypersensitivities. Hypersensitivity Robert Beatty Type I Type II Type III Type IV MCB150 IgE Mediated IgG/IgM Mediated IgG Mediated T cell Classic Allergy rbc lysis Immune
More informationCancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
More informationB cell activation and Humoral Immunity
B cell activation and Humoral Immunity Humoral immunity is mediated by secreted antibodies and its physiological function is defense against extracellular microbes (including viruses) and microbial exotoxins.
More informationActions of Hormones on Target Cells Page 1. Actions of Hormones on Target Cells Page 2. Goals/ What You Need to Know Goals What You Need to Know
Actions of Hormones on Target Cells Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1. Actions of Hormones on Target Cells Hormones
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationHUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES JASON CYSTER SECTION 13
SECTION 13 HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES CONTACT INFORMATION Jason Cyster, PhD (Email) READING Basic Immunology: Functions and Disorders of the Immune System. Abbas,
More informationCore Topic 2. The immune system and how vaccines work
Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationMicro RNAs: potentielle Biomarker für das. Blutspenderscreening
Micro RNAs: potentielle Biomarker für das Blutspenderscreening micrornas - Background Types of RNA -Coding: messenger RNA (mrna) -Non-coding (examples): Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationSolid Organ Transplantation in Singapore
Solid Organ Transplantation in Singapore Prof A Vathsala Head, Division of Nephrology Director, Adult Transplantation Department of Medicine National University Hospital 1960 Timeline of Transplantation
More informationThe Human Immune System
The Human Immune System What is the immune system? The body s defense against disease causing organisms, malfunctioning cells, and foreign particles The First Line of Defense Skin The dead, outer layer
More informationDendritic Cells: A Basic Review *last updated May 2003
*last updated May 2003 Prepared by: Eric Wieder, PhD MD Anderson Cancer Center Houston, TX USA What is a dendritic cell? Dendritic cells are antigen-presenting cells (APCs) which play a critical role in
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationCD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
More informationVersion 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen
Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical
More informationChapter 16: Innate Immunity
Chapter 16: Innate Immunity 1. Overview of Innate Immunity 2. Inflammation & Phagocytosis 3. Antimicrobial Substances 1. Overview of Innate Immunity The Body s Defenses The body has 2 types of defense
More informationAntibody-mediated rejection after kidney transplantation
Antibody-mediated rejection after kidney transplantation an overview of current treatment options Systematic review Varsha V. Jharap a, Manah Ahmadi a, Saskia A.M.E. van Diessen b,, Ajda T. Rowshani c
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationInflammation and Healing. Review of Normal Defenses. Review of Normal Capillary Exchange. BIO 375 Pathophysiology
Inflammation and Healing BIO 375 Pathophysiology Review of Normal Defenses Review of Normal Capillary Exchange 1 Inflammation Inflammation is a biochemical and cellular process that occurs in vascularized
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationHuman Leukocyte Antigens - HLA
Human Leukocyte Antigens - HLA Human Leukocyte Antigens (HLA) are cell surface proteins involved in immune function. HLA molecules present antigenic peptides to generate immune defense reactions. HLA-class
More informationFrequency Of Autoreactive T Cells 3/5/2014. Circulation Of Activated Cells To The CNS
Immune Basis of New MS Therapies Samia J Khoury, MD Director of Abou-Haidar Neuroscience Institute Director of Multiple Sclerosis Center Professor of Neurology AUBMC MS Center & Harvard Medical School
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationChapter 14: The Lymphatic System and Immunity
Chapter 14: The Lymphatic System and Immunity Major function of the Lymphatic System o Network of vessels that collect and carry excess fluid from interstitial spaces back to blood circulation o Organs
More informationFinal Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism.
Central Dogma Final Review Section Week 10 DNA RNA Protein DNA DNA replication DNA RNA transcription RNA Protein translation **RNA DNA reverse transcription http://bass.bio.uci.edu/~hudel/bs99a/lecture20/lecture1_1.html
More informationThe Body s Defenses CHAPTER 24
CHAPTER 24 The Body s Defenses PowerPoint Lectures for Essential Biology, Third Edition Neil Campbell, Jane Reece, and Eric Simon Essential Biology with Physiology, Second Edition Neil Campbell, Jane Reece,
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationImmune Basis of New MS Therapies
Immune Basis of New MS Therapies Samia J Khoury, MD Director of Abou-Haidar Neuroscience Institute Director of Multiple Sclerosis Center Professor of Neurology AUBMC MS Center & Harvard Medical School
More informationTREATING AUTOIMMUNE DISEASES WITH HOMEOPATHY. Dr. Stephen A. Messer, MSEd, ND, DHANP Professor and Chair of Homeopathic Medicine
TREATING AUTOIMMUNE DISEASES WITH HOMEOPATHY Dr. Stephen A. Messer, MSEd, ND, DHANP Professor and Chair of Homeopathic Medicine AUTOIMMUNE DISEASES An autoimmune disorder occurs when the body s immune
More informationHow To Remove A Drug By Therapeutic Apheresis
Medication Removal by Apheresis Yanyun Wu, M.D., Ph.D. Yale University School of Medicine 1 Objectives Review basic pharmacokinetics and its relevance in drug removal by therapeutic apheresis (TPE) Review
More informationBasics of Immunology
Basics of Immunology 2 Basics of Immunology What is the immune system? Biological mechanism for identifying and destroying pathogens within a larger organism. Pathogens: agents that cause disease Bacteria,
More informationPh.D. in Molecular Medicine
Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to
More informationEffectively Exploiting Big Data with Semantics
Effectively Exploiting Big Data with Semantics Thomas C. Rindflesch, Ph.D. National Library of Medicine, National Institutes of Health Digital Government Institute s Government Big Data Conference, October
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationActive Clinical Trials
Active Clinical Trials 1. Genentech Efalizumab Protocol No. ACD4230g Title: A Phase II/III, Randomized, Open-Label, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationMolecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
More informationTHE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.
More informationImmunology and immunotherapy in allergic disease
Immunology and immunotherapy in allergic disease Jing Shen, MD Faculty Advisor: Matthew Ryan, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation February 2005
More informationTABLE OF CONTENT. Page ACKNOWLEDGEMENTS. iii ENGLISH ABSTRACT THAI ABSTRACT. vii LIST OF TABLES LIST OF FIGURES. xvi ABBREVIATIONS.
x TABLE OF CONTENT ACKNOWLEDGEMENTS ENGLISH ABSTRACT THAI ABSTRACT LIST OF TABLES LIST OF FIGURES ABBREVIATIONS iii iv vii xv xvi xviii CHAPTER I: INTRODUCTION 1.1 Statement of problems 1 1.2 Literature
More informationBone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital
Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.
More information